| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Ipratropium bromide is an anticholinergic (parasympatholytic) agent tha appears to inhibit vagally mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve.Anticholinergics prevent the increases in intracellular concentration of cyclic guanosine monophosphate (cyclic GMP) that are caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle. Ipratropium is used to treat a runny nose caused by the common cold or seasonal allergies.
| ln Vitro |
In 15 minutes, ipratropium bromide hydrate (1 nM, 10 nM, 100 nM) causes damage to mitochondrial membrane potential [1]. In 4 hours, ipratropium bromide hydrate (1 nM-1 μM) increases infarct size in ischemia/reperfusion experiments in isolated perfused hearts [1], and in 2 hours, ipratropium bromide hydrate (0.001 nM-0.1 mM) inhibits the growth of adult rat cardiomyocytes following 4 hours of hypoxia [1].
|
|---|---|
| ln Vivo |
Ipratropium bromide hydrate (1.0 μg/kg; IV; single dosage) potentiates vagal nerve stimulation that produces bronchoconstriction [2]. Ipratropium bromide hydrate (0.04 mg/20 mL and 0.20 mg/20 mL; inhalation over 30 minutes, rate=30 mL/30 minutes) protects the lungs from cadmium by lowering parenchymal inflammatory infiltration of neutrophils Effects of induced acute neutrophilic inflammation. 4].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: adult rat cardiomyocytes Tested Concentrations: 0.001 nM-0.1 mM Incubation Duration: 2 hrs (hours) in the dark; 4 hrs (hours) before hypoxia Experimental Results: Cell viability was dose-dependent, and the inhibition rate was at the 0.1 mM dose 52.7%. |
| Animal Protocol |
Animal/Disease Models: Dunkin Hartley strain guinea pig [2]
Doses: 0.1-1 μg/kg Route of Administration: intravenous (iv) (iv)injection; intravenous (iv) (iv)injection. Single dose Experimental Results: 0.3 μg/kg had little blocking effect on postligation muscarinic receptors, and 0.5 μg/kg inhibited ACh-induced bronchoconstriction. Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat (300-350 g) [4] Doses: 0.04 mg/20 mL and 0.20 mg/20 mL Route of Administration: Inhalation; Inhalation; Nebulization rate 30 mL/30 minutes; 30 minute Experimental Results: Has no significant effect on any parameters recorded in healthy rats, but has a protective effect on cadmium-induced inflammatory responses. |
| References |
[1]. Fryer AD, et al. Maclagan, Ipratropium bromide potentiates bronchoconstriction induced by vagal nerve stimulation in the guinea-pig. Eur J Pharmacol, 1987. 139(2): p. 187-91.
[2]. Harvey, et al. Maddock, Ipratropium Bromide-Mediated Myocardial Injury in In Vitro Models of Myocardial Ischaemia/Reperfusion. Toxicol Sci, 2014. [3]. Maria Prat, et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl amides as potent and long acting muscarinic antagonists. Bioorg Med Chem Lett. 2015 Apr 15;25(8):1736-1741. [4]. Wenhui Zhang, et al. Anti-inflammatory effects of formoterol and ipratropium bromide against acute cadmium-induced pulmonary inflammation in rats. Eur J Pharmacol. 2010 Feb 25;628(1-3):171-8. [5]. Venkatasamy R, et al. Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility. Br J Pharmacol. 2016 Aug;173(15):2335-51. |
| Molecular Formula |
C20H32BRNO4
|
|---|---|
| Molecular Weight |
430.3764
|
| CAS # |
66985-17-9
|
| Related CAS # |
Ipratropium bromide;22254-24-6;Ipratropium-d3 bromide;Ipratropium-d7 bromide
|
| SMILES |
[Br-].O(C(C([H])(C1C([H])=C([H])C([H])=C([H])C=1[H])C([H])([H])O[H])=O)C1([H])C([H])([H])C2([H])C([H])([H])C([H])([H])C([H])(C1([H])[H])[N+]2(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])[H].O([H])[H]
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~62.5 mg/mL (~145.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (116.18 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3235 mL | 11.6176 mL | 23.2353 mL | |
| 5 mM | 0.4647 mL | 2.3235 mL | 4.6471 mL | |
| 10 mM | 0.2324 mL | 1.1618 mL | 2.3235 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
